Juan L. Bayo

Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer

Magdalena Ruiz, J. Salvador, Juan L. Bayo et al. · Cancer Chemotherapy and Pharmacology · 2008 · 30 citations

Weekly Schedule, Breast Oncology, Oncology +5

Perinatal and childhood factors and risk of breast cancer subtypes in adulthood

Virginia Lope, Esther García‐Esquinas, Beatriz Pérez‐Gómez et al. · Cancer Epidemiology · 2015 · 20 citations · Full text

Breast Oncology, Cancer Risk, Cancer Epidemiology +12

Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer

Juan L. Bayo, José Mayordomo, Pedro Sánchez‐Rovira et al. · Journal of Clinical Oncology · 2004 · 12 citations

Metastatic Breast Cancer, Oncology, Vinorelbine Combination +13

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

J. Salvador, Luís Manso, Juan de la Haba-Rodríguez et al. · Clinical & Translational Oncology · 2014 · 12 citations · Full text

First-line Therapy, Breast Oncology, Oncology +7

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer

Isabel Blancas, C Olier, V. Conde et al. · Scientific Reports · 2021 · 11 citations · Full text